Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study - Summary - MDSpire

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study

  • By

  • Ronja Hietikko

  • Tuomas Mirtti

  • Tuomas P. Kilpeläinen

  • Teemu Tolonen

  • Anne Räisänen-Sokolowski

  • Stig Nordling

  • Jill Hannus

  • Marita Laurila

  • Kimmo Taari

  • Teuvo L. J. Tammela

  • Reija Autio

  • Kari Natunen

  • Anssi Auvinen

  • Antti Rannikko

  • April 6, 2024

  • 0 min

Share

Objective:

To evaluate MRI-targeted biopsy related interreader variability and its expected impact on the ProScreen trial, which aims to minimize overdiagnosis while maintaining prostate cancer mortality reduction.

Key Findings:
  • Complete agreement on Gleason grade among all pathologists in 21.2% of cases.
  • Consensus (at least 2/3 agreement) was reached in 65.9% of cases.
  • No consensus was reached in 34.1% of cases, with the most common disagreement being the estimated proportion of cancer.
Interpretation:

The study highlights significant interreader variability among pathologists interpreting MRI-targeted biopsies, which may impact treatment decisions in the ProScreen trial.

Limitations:
  • Small sample size of 85 biopsies analyzed, which may limit the generalizability of the findings.
  • Lack of formal common training for pathologists, potentially contributing to variability in interpretations.
Conclusion:

Interreader variability in MRI-targeted biopsy interpretations is notable and could influence outcomes in prostate cancer screening trials, highlighting the need for standardized training and assessment protocols.

Original Source(s)

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study

  • by Ronja Hietikko, Tuomas Mirtti, Tuomas P. Kilpeläinen, Teemu Tolonen, Anne Räisänen-Sokolowski, Stig Nordling, Jill Hannus, Marita Laurila, Kimmo Taari, Teuvo L. J. Tammela, Reija Autio, Kari Natunen, Anssi Auvinen, Antti Rannikko

  • April 6, 2024

Related Content

T2 mapping for the characterization of prostate lesions

Illumination matters Part III: Impact of light obstruction on illuminance from flexible ureteroscopes — a comparative PEARLS analysis

Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study